ReForm Biologics and KBI Biopharma have entered a strategic partnership to make improved biopharmaceutical formulations. 

Through this collaboration, KBI and ReForm will help customers extend product lifecycles, enable improved dosing for patients, and enhance manufacturing efficiencies. As part of the strategic partnership, KBI has made an equity investment in ReForm Biologics.

KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. ReForm’s proprietary excipient technologies decrease viscosity and enhance stability, thereby enabling subcutaneous and improved device-assisted administration that can enable biopharmaceutical companies to expand market share and maximize value creation via product line extension.

As part of the collaboration, KBI will provide services to ReForm to further develop and validate its biologic formulation platform while also gaining access to ReForm’s proprietary technology. Reform will maintain the ability to utilize its formulation technologies directly with its pharmaceutical and biotechnology partners. Financial terms of the agreement were not disclosed.

“We are very excited to collaborate with ReForm and leverage their enabling formulation technology to advance the programs of our client partners,” said Tim Kelly Ph.D., president and chief executive officer of KBI. “KBI has a long-standing track record of leadership in the formulation of biologics, and ReForm’s unique technology will help us address some of the biggest challenges in protein formulation. Together, KBI and ReForm will help transform our clients’ most innovative pipeline discoveries into viable commercial products to treat patients.”

“This collaboration brings together ReForm’s innovative formulation platforms with KBI’s deep industry experience and global customer base,” said John M. Sorvillo PhD, chief executive officer at ReForm. “Access to KBI’s services and customers will allow us to advance our technologies more rapidly and generate additional revenues for both companies. We are pleased to have KBI as a shareholder and strategic partner as we expand our transformative platforms for biotherapeutic formulations, for the benefit of patients.”

Along with KBI’s equity investment, ReForm Biologics’ existing investors, including Phoenix Venture Partners, participated in the investment round.